STM publisher Elsevier has announced Embase, which claims to be the world's most comprehensive biomedical database that enables tracking and retrieval of drug-specific data, has been enhanced to support the retrieval of medical device information. The improvements support comprehensive post-market surveillance and device safety as well as the development of novel devices.
Embase, which is part of the Elsevier Life Science Solutions portfolio, will help users prepare for clinical evaluations and perform post-market surveillance for medical devices more effectively through newly added functionality.
Medical device manufacturers using Embase will be able to carry out systematic reviews and compile a range of technological reviews including health technology assessments, rapid advisories, comparative effectiveness reviews and clinical evaluations for a medical device. Users will be able to monitor the literature for adverse device effects, emerging public health threats, quality complaints and inaccurate or inappropriate statements on devices.
Data from Embase can be delivered in a flexible manner, allowing for better integration with customers' existing workflows and tools for post market surveillance. Customers can also incorporate data into their alerting systems to drive a more effective monitoring process with comprehensive information on regulatory changes and adverse events. Additionally, Embase works together with QUOSA, Elsevier's scientific literature management solution supporting retrieval, storage, tagging and annotation of scientific literature to deliver an end-to-end workflow for the screening, organizing, archiving and sharing of medical device literature.
